Investigation of Extended-Spectrum β-Lactamase and Carbapenemase Producing Gram-Negative Bacilli in Rectal Swabs Collected from Neonates and Their Associated Factors in Neonatal Intensive Care Units of Southern Ethiopia.
carbapenemase
extended-spectrum β-lactamase
gram-negative bacilli
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
08
2021
accepted:
15
09
2021
entrez:
30
9
2021
pubmed:
1
10
2021
medline:
1
10
2021
Statut:
epublish
Résumé
Currently extended-spectrum β-lactamase (ESβL) and carbapenemase producing gram-negative bacteria are the greatest concern among the neonatal population with very limited therapeutic options. The aim of this study was to assess the prevalence of ESβL and carbapenemase producing gram-negative bacilli, associated factors and antimicrobial resistance patterns among neonates in intensive care units. An institutional-based cross-sectional study was conducted from February to June 2021 on 212 neonates in intensive care units. Risk factors data were collected by using a well-designed questionnaire. A rectal swab sample was collected using a sterile cotton swab and inoculated on MacConkey agar. Bacterial isolates were identified using various biochemical tests. ESβL and carbapenemase were first screened by indicator cephalosporins (cefotaxime (30µg) and ceftazidine (30µg)) and carbapenem (meropenem and ertapenem), respectively. ESβL and carbapenemase were confirmed by a double-disk synergy test and modified carbapenem inactivation methods, respectively. SPSS version 21.0 was used for data analysis. A P-value ≤ 0.05 was considered as statistically significant. The overall prevalence of ESβL-producing gram-negative bacilli was 72/212 (34%). The predominant ESβL-producing isolate was A high prevalence of ESβL-producing bacterial isolates was observed for commonly used antibiotics which needs further attention. Therefore, continuous and regular follow-ups of drug resistance patterns is important for the proper treatment and management of ESβL and carbapenemase producing gram-negative bacilli.
Sections du résumé
BACKGROUND
BACKGROUND
Currently extended-spectrum β-lactamase (ESβL) and carbapenemase producing gram-negative bacteria are the greatest concern among the neonatal population with very limited therapeutic options. The aim of this study was to assess the prevalence of ESβL and carbapenemase producing gram-negative bacilli, associated factors and antimicrobial resistance patterns among neonates in intensive care units.
METHODS
METHODS
An institutional-based cross-sectional study was conducted from February to June 2021 on 212 neonates in intensive care units. Risk factors data were collected by using a well-designed questionnaire. A rectal swab sample was collected using a sterile cotton swab and inoculated on MacConkey agar. Bacterial isolates were identified using various biochemical tests. ESβL and carbapenemase were first screened by indicator cephalosporins (cefotaxime (30µg) and ceftazidine (30µg)) and carbapenem (meropenem and ertapenem), respectively. ESβL and carbapenemase were confirmed by a double-disk synergy test and modified carbapenem inactivation methods, respectively. SPSS version 21.0 was used for data analysis. A P-value ≤ 0.05 was considered as statistically significant.
RESULTS
RESULTS
The overall prevalence of ESβL-producing gram-negative bacilli was 72/212 (34%). The predominant ESβL-producing isolate was
CONCLUSION
CONCLUSIONS
A high prevalence of ESβL-producing bacterial isolates was observed for commonly used antibiotics which needs further attention. Therefore, continuous and regular follow-ups of drug resistance patterns is important for the proper treatment and management of ESβL and carbapenemase producing gram-negative bacilli.
Identifiants
pubmed: 34588786
doi: 10.2147/IDR.S333603
pii: 333603
pmc: PMC8476106
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3907-3917Informations de copyright
© 2021 Zakir et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests in this work.
Références
Curr Opin Infect Dis. 2008 Aug;21(4):350-6
pubmed: 18594285
Infect Control Hosp Epidemiol. 2018 Dec;39(12):1436-1441
pubmed: 30345942
J Antimicrob Chemother. 2020 Jan 1;75(1):77-85
pubmed: 31613964
Curr Opin Infect Dis. 2017 Aug;30(4):395-403
pubmed: 28582313
J Hosp Infect. 2013 Mar;83(3):196-9
pubmed: 23374289
Am J Infect Control. 2019 Jan;47(1):105-108
pubmed: 30220617
PLoS One. 2013 Oct 11;8(10):e76597
pubmed: 24146896
Infection. 2020 Dec;48(6):853-860
pubmed: 32462287
J Glob Antimicrob Resist. 2016 Dec;7:114-118
pubmed: 27750157
PLoS One. 2016 Aug 30;11(8):e0161685
pubmed: 27574974
J Infect Dev Ctries. 2020 Jul 31;14(7):765-771
pubmed: 32794468
J Glob Antimicrob Resist. 2017 Mar;8:90-96
pubmed: 28039104
Medicine (Baltimore). 2016 Mar;95(10):e3016
pubmed: 26962817
Infect Drug Resist. 2020 May 22;13:1517-1526
pubmed: 32547121
J Hosp Infect. 2009 Apr;71(4):340-7
pubmed: 19147256
Am J Infect Control. 2014 Mar;42(3):277-82
pubmed: 24581016
BMC Res Notes. 2014 May 03;7:279
pubmed: 24886506
Heliyon. 2019 Sep 17;5(9):e02349
pubmed: 31687535
Clin Infect Dis. 2019 Aug 16;69(5):751-759
pubmed: 30830952
P T. 2019 Apr;44(4):192-200
pubmed: 30930604
Open Forum Infect Dis. 2020 Mar 28;7(4):ofaa109
pubmed: 32373647
Infect Drug Resist. 2020 May 06;13:1319-1326
pubmed: 32440169
J Infect Dev Ctries. 2013 Aug 15;7(8):630-4
pubmed: 23949299
Early Hum Dev. 2014 Mar;90 Suppl 1:S4-6
pubmed: 24709456
Rev Invest Clin. 2015 Sep-Oct;67(5):313-7
pubmed: 26696335
Mol Biol Rep. 2020 Sep;47(9):7097-7106
pubmed: 32894435
Isr Med Assoc J. 2018 May;20(5):286-290
pubmed: 29761673
Infect Drug Resist. 2018 Aug 08;11:1097-1104
pubmed: 30127627
Int J Antimicrob Agents. 2017 Nov;50(5):622-628
pubmed: 28733213
Biomed Res Int. 2013;2013:756209
pubmed: 24175299
J Antimicrob Chemother. 2014 Aug;69(8):2230-7
pubmed: 24729603